AFMD - アフィメド (Affimed N.V.) アフィメド

 AFMDのチャート


 AFMDの企業情報

symbol AFMD
会社名 Affimed N.V. (アフィメド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13 AFM11 AFM21 AFM22 AFM24 TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22 which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.   アフィメドはドイツのバイオ医薬品会社の持株会社。同社は2000年設立。ハイデルベルクのドイツがん研究センタ―で開発された技術をもとに、腫瘍細胞への自己免疫力を高める革新的なアプロ―チによるがん治療法の研究、開発、商品化に従事。開発中の製品にAFM13、AFM11、AFM21を含む。   Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
本社所在地 Technologiepark Im Neuenheimer Feld 582 Heidelberg 69120 DEU
代表者氏名 Thomas Hecht トーマス・ヘクト
代表者役職名 Chairman of the Supervisory Board
電話番号 +49 6221-67-4360
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.affimed.com
nasdaq_url https://www.nasdaq.com/symbol/afmd
adr_tso
EBITDA EBITDA(百万ドル) -34.24747
終値(lastsale) 4.62
時価総額(marketcap) 288242114.16
時価総額 時価総額(百万ドル) 218.36520
売上高 売上高(百万ドル) 2.05078
企業価値(EV) 企業価値(EV)(百万ドル) 170.73193
当期純利益 当期純利益(百万ドル) -35.31480
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Affimed NV revenues decreased 25% to EUR682K. Net loss increased 3% to EUR16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development expenses - Bala increase of 23% to EUR13.1M (expense) Interest Expense Net increase from EUR168K to EUR466K (expense).

 AFMDのテクニカル分析


 AFMDのニュース

   Covid-19 Analysis: Bispecific Antibody Market 2020 Size, Share, Trends and Analysis of Leading Players- Affimed Therapeutics, Genmab, EMD Serono, Regeneron Pharmaceuticals, Roche, Chugai Pharmaceutical  2020/10/19 09:28:10 OpenPR
The Bispecific Antibody market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Bispecific Antibody market report is a comprehensive research that
   The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  2020/07/10 11:25:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (NASDAQ: NEO ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Penumbra Inc (NYSE: PEN ) Qiagen NV ( NYSE: QGEN ) Quidel Corporation (NASDAQ: QDEL ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) TG Therapeutics Inc (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 9) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) immatics biotechnologies GmbH (NASDAQ: IMTX ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Polypid Ltd (NASDAQ: PYPD ) Recro Pharma Inc (NASDAQ: REPH ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Ziopharm Announces Initiation of Phase 1 Trial For Blood Cancer Cell Therapy ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) said it has initiated a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, or …
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Affimed N.V. (NASDAQ: AFMD) Q1 2020 Earnings Call Transcript  2020/06/23 20:23:54 News Alphastreet
Affimed N.V. (AFMD) Q1 2020 earnings call dated Jun. 23, 2020 Corporate Participants: Alexander Fudukidis — Head of Investor Relations Adi Hoess — Chief Executive Officer Arndt Schottelius — Chief Scientific Officer Andreas Harstrick — Chief Medical Officer Michael Wolf — Head of Finance Wolfgang Fischer — Chief Operating Officer Analysts: Maury Raycroft — Jefferies — Analyst Jim Birchenough — Wells Fargo — Analyst Yale Jen — Laidlaw & Company — Analyst Ike […]
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  2020/07/10 11:25:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (NASDAQ: NEO ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Penumbra Inc (NYSE: PEN ) Qiagen NV ( NYSE: QGEN ) Quidel Corporation (NASDAQ: QDEL ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) TG Therapeutics Inc (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 9) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) immatics biotechnologies GmbH (NASDAQ: IMTX ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Polypid Ltd (NASDAQ: PYPD ) Recro Pharma Inc (NASDAQ: REPH ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Ziopharm Announces Initiation of Phase 1 Trial For Blood Cancer Cell Therapy ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) said it has initiated a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, or …
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Affimed N.V. (NASDAQ: AFMD) Q1 2020 Earnings Call Transcript  2020/06/23 20:23:54 News Alphastreet
Affimed N.V. (AFMD) Q1 2020 earnings call dated Jun. 23, 2020 Corporate Participants: Alexander Fudukidis — Head of Investor Relations Adi Hoess — Chief Executive Officer Arndt Schottelius — Chief Scientific Officer Andreas Harstrick — Chief Medical Officer Michael Wolf — Head of Finance Wolfgang Fischer — Chief Operating Officer Analysts: Maury Raycroft — Jefferies — Analyst Jim Birchenough — Wells Fargo — Analyst Yale Jen — Laidlaw & Company — Analyst Ike […]
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference  2020/06/16 10:30:00 GlobeNewswire
Heidelberg, Germany, June 16, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate…
   The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  2020/07/10 11:25:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (NASDAQ: NEO ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Penumbra Inc (NYSE: PEN ) Qiagen NV ( NYSE: QGEN ) Quidel Corporation (NASDAQ: QDEL ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) TG Therapeutics Inc (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 9) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) immatics biotechnologies GmbH (NASDAQ: IMTX ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Polypid Ltd (NASDAQ: PYPD ) Recro Pharma Inc (NASDAQ: REPH ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Ziopharm Announces Initiation of Phase 1 Trial For Blood Cancer Cell Therapy ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) said it has initiated a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, or …
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Affimed N.V. (NASDAQ: AFMD) Q1 2020 Earnings Call Transcript  2020/06/23 20:23:54 News Alphastreet
Affimed N.V. (AFMD) Q1 2020 earnings call dated Jun. 23, 2020 Corporate Participants: Alexander Fudukidis — Head of Investor Relations Adi Hoess — Chief Executive Officer Arndt Schottelius — Chief Scientific Officer Andreas Harstrick — Chief Medical Officer Michael Wolf — Head of Finance Wolfgang Fischer — Chief Operating Officer Analysts: Maury Raycroft — Jefferies — Analyst Jim Birchenough — Wells Fargo — Analyst Yale Jen — Laidlaw & Company — Analyst Ike […]
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference  2020/06/16 10:30:00 GlobeNewswire
Heidelberg, Germany, June 16, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アフィメド AFMD Affimed N.V.)

 twitter  (公式ツイッターやCEOツイッターなど)